Effect of alendronate and vitamin D3 on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women

2011 ◽  
Vol 26 (8) ◽  
pp. 1836-1844 ◽  
Author(s):  
Sue A Shapses ◽  
David L Kendler ◽  
Richard Robson ◽  
Karen E Hansen ◽  
Robert M Sherrell ◽  
...  
Keyword(s):  
Vitamin D3 ◽  
Calcium Absorption ◽  
Controlled Trial ◽  
Double Blind ◽  
Fractional Calcium Absorption

Tu1876 A PILOT DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL ON VITAMIN D3 IN CHILDREN WITH NEWLY DIAGNOSED CROHN'S DISEASE

2020 ◽  
Vol 158 (6) ◽  
pp. S-1199-S-1200
Author(s):  
Samuel Sassine ◽  
Sonia Alexandra Tchogna ◽  
Colette Deslandres ◽  
Geneviève Mailhot ◽  
Nathalie Alos ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Vitamin D3 ◽  
Controlled Trial ◽  
Newly Diagnosed ◽  
Double Blind ◽  
Randomized Controlled

scholarly journals High-dose vitamin D3 in adults with pulmonary tuberculosis: a double-blind randomized controlled trial

2015 ◽  
Vol 102 (5) ◽  
pp. 1059-1069 ◽  
Author(s):  
Nestan Tukvadze ◽  
Ekaterina Sanikidze ◽  
Maia Kipiani ◽  
Gautam Hebbar ◽  
Kirk A Easley ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Pulmonary Tuberculosis ◽  
Vitamin D3 ◽  
Controlled Trial ◽  
High Dose ◽  
Double Blind ◽  
Randomized Controlled ◽  
High Dose Vitamin

scholarly journals Effect of Calcium or 25OH Vitamin D3 Dietary Supplementation on Bone Loss at the Hip in Men and Women over the Age of 60*

2000 ◽  
Vol 85 (9) ◽  
pp. 3011-3019 ◽  
Author(s):  
Munro Peacock ◽  
Guangda Liu ◽  
Mark Carey ◽  
Ronald McClintock ◽  
Walter Ambrosius ◽  
...  
Keyword(s):  
Bone Loss ◽  
Bone Turnover ◽  
Secondary Hyperparathyroidism ◽  
Vitamin D3 ◽  
Bone Structure ◽  
Controlled Trial ◽  
Drop Out ◽  
Mineral Density ◽  
Serious Adverse Events ◽  
Double Blind

Abstract Dietary supplements that prevent bone loss at the hip and that can be applied safely in the elderly are likely to reduce hip fractures. A daily dietary supplement of 750 mg calcium or 15 μg 25OH vitamin D3 on bone loss at the hip and other sites, bone turnover and calcium-regulating hormones were studied over 4 yr in elderly volunteers using a randomized, double-blind, placebo-controlled trial. Bone mineral density (BMD) was measured by dual x-ray absorptiometry and bone structure by radiographs. Calcium biochemistry and bone turnover markers were measured in blood and urine. The 316 women entering the trial had a mean age of 73.7 yr and the 122 men of 75.9 yr. Baseline median calcium intake was 546 mg/day, and median serum 25OH vitamin D3 was 59 nmol/L. On placebo, loss of BMD at total hip was 2% and femoral medulla expansion was 3% over 4 yr. Calcium reduced bone loss, secondary hyperparathyroidism, and bone turnover. 25OH vitamin D3 was intermediate between placebo and calcium. Fracture rates and drop-out rates were similar among groups, and there were no serious adverse events with either supplement. A calcium supplement of 750 mg/day prevents loss of BMD, reduces femoral medullary expansion, secondary hyperparathyroidism, and high bone turnover. A supplement of 15 μg/day 25OH vitamin D3 is less effective, and because its effects are seen only at low calcium intakes, suggests that its beneficial effect is to reverse calcium insufficiency.

Sign in / Sign up

Export Citation Format

Share Document